Related Experiment Video
Updated: Jul 18, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Cellular cardiomyoplasty by catheter-based infusion of stem cells in clinical settings
Haiyan Qian1, Yuejin Yang, Ji Huang
1Department of Cardiology, Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Science and Peaking Union Medical College, 167 BeiLiShi Rd, Beijing 100037, P.R. China.
Insights
Cellular cardiomyoplasty using stem cells shows promise for heart repair after myocardial infarction. Catheter-based delivery offers a safer, less invasive alternative to traditional methods for clinical application.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Biomedical Engineering
Background:
- Myocardial infarction (MI) is a primary cause of heart failure and mortality.
- The heart's natural repair mechanisms are insufficient to replace lost cardiomyocytes.
- Current therapies do not fully prevent adverse ventricular remodeling post-MI.
Purpose of the Study:
- To review advancements in catheter-based stem cell transplantation for myocardial infarction.
- To understand the clinical application of intervention-based stem cell delivery methods.
- To highlight the potential of cellular cardiomyoplasty in cardiac repair.
Main Methods:
- Review of experimental studies and clinical trials on stem cell transplantation for MI.
- Focus on catheter-based infusion techniques versus traditional intramyocardial injection.
- Analysis of safety, convenience, and efficacy of different delivery approaches.
Main Results:
- Cellular cardiomyoplasty with stem cells may improve cardiac perfusion and function after MI.
- Catheter-based stem cell delivery is a safe, convenient, and minimally invasive clinical approach.
- Ongoing research aims to optimize stem cell delivery to targeted cardiac areas.
Conclusions:
- Cellular cardiomyoplasty represents a promising therapeutic strategy for post-MI cardiac regeneration.
- Catheter-based stem cell transplantation is emerging as a preferred clinical method.
- Further research is needed to refine stem cell delivery and elucidate underlying mechanisms.
Abstract:
Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. However, the intrinsic repair mechanism of the heart is inadequate. Current therapy is limited in preventing ventricular remodeling, but can not regenerate the lost cardiomyocytes. Recent interests have been focused on cellular cardiomyoplasty which is an outside intervention to support the reparative process in the heart through transplantation of stem/progenitor cells or cardiac cells. Cellular cardiomyoplasty with stem cells is a possible option to reverse the adverse hemodynamic and neurohormonal imbalance after myocardial infarction. Experimental studies and clinical trials suggest that cellular cardiomyoplasty may benefit tissue perfusion and contractile performance of the injured heart. Although the mechanisms are still intensively debated, cellular cardiomyoplasty with stem cells has already been introduced into the clinical settings. However, it is an important challenge how stem cells are delivered to targeted area. In early studies on animals, intramyocardial injection of stem cells after thoracotomy is the predominant transplantation route which is not suitable for most patients in clinical settings. Then the catheter-based infusion of stem cells is clinically introduced and rapidly developed in patients because of the safety, convenience and mini-invasion. We mainly review the progress in catheter-based transplantation with stem cells in order to fully understand the application of various intervention-based approaches to stem cells transplantation in clinical settings.
